PACB (Pacific Biosciences of California) Total Debt per Share: $2.27 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PACB Pacific Biosciences of California Inc PACB
55 GF Score
Price $1.39
GF Value $1.62
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Total Debt per Share?

Pacific Biosciences of California PACB 55 Total Debt per Share is $2.27 as of Mar. 2026. GuruFocus rates PACB with a GF Score™ of 55/100 and a GF Value™ of $1.62 (Modestly Undervalued). The stock has 6 warning signs investors should review.

$2.27 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Pacific Biosciences of California's Total Debt Per Share for the quarter that ended in Mar. 2026 was $2.27.

Pacific Biosciences of California Total Debt per Share Related Terms

Pacific Biosciences of California Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Pacific Biosciences of California's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California Total Debt per Share Chart

Pacific Biosciences of California Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.32 4.19 3.49 2.28 2.33

Pacific Biosciences of California Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 2.33 2.32 2.33 2.27
PACB
55GF Score
Pacific Biosciences of California Inc PACB
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Biosciences of California Total Debt per Share Calculation

Pacific Biosciences of California's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(702.0+0.4)/302.0
=2.33

Pacific Biosciences of California's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(703.1+0.3)/310.5
=2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $2.27 mean?
Pacific Biosciences of California (PACB) has a Total Debt per Share of $2.27 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Total Debt per Share too high?
Pacific Biosciences of California's current Total Debt per Share is $2.27. Overall, Pacific Biosciences of California has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Total Debt per Share compare to DCTH and CLPT?
Pacific Biosciences of California's Total Debt per Share of $2.27 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Total Debt per Share is $2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.62, compared to a current price of $1.39 — trading 14.5% below its estimated fair value. The current Total Debt per Share is $2.27. Pacific Biosciences of California's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Total Debt per Share is $2.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of $1.39 is trading 14.5% below its estimated GF Value™ of $1.62. GuruFocus considers Pacific Biosciences of California to be Modestly Undervalued.

Key valuation signals for PACB:

  • Total Debt per Share: $2.27
  • GF Value™: $1.62 vs. price of $1.39 (14.5% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
55GF Score

Get the complete analysis for PACB

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$1.62
GF Value